Full Press Release Details
Aditxt Opens its First High-Capacity Immune
Monitoring Center in
AditxtScoreTM Center to Become Global
Headquarters for Aditxt as a Biotech
Innovator Focused on Immune Health
Richmond, VA - DATE, 2021 - Aditxt, Inc. (Nasdaq: ADTX),
a biotech innovation company with a mission to improve the health of the immune system, today announced the opening of its AditxtScore
Center in Richmond, VA. This high-capacity, CLIA-validated immune monitoring center will be capable of processing several million
complex immune system reports per year.
"The opening of the AditxtScore Center is a key step on AditxtScore's
path to market, serving as a critical enabler to commercializing a new platform for personalized health," said Amro Albanna, Co-founder
and Chief Executive Officer of Aditxt. "In addition to its operational and commercial capabilities, this facility will also help
accelerate new AditxtScore application development activities to address markets with significant growth potential. We believe it will
now be possible to rethink the way providers diagnose and treat disease through a deeper, more nuanced understanding of the immune system."
Introduced earlier this year in a joint press conference with Governor
Ralph Northam, Richmond Mayor Levar Stoney and other local business executives and political officials, the AditxtScore
Center was built to support the growth of the AditxtScore platform, a pioneering new approach to immune and health monitoring that provides
a personalized profile of the immune system. By assessing an individual's immune biomarkers, AditxtScore is designed to measure indications
of immune response to specific disease. AditxtScore applications include the recently commercialized AditxtScore for COVID-19, developed
for use in detecting antibodies and neutralizing antibodies against SARS-CoV-2 antigens.
AditxtScore is offered through authorized channel partners. To find
an AditxtScore Channel Partner near you, please visit www.aditxtscore.com. AditxtScore is available for use as a CLIA-validated laboratory
developed test (LDT). This test is not for self-diagnosis and is not cleared or approved by the FDA.
Aditxt is developing technologies specifically focused on improving
the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to
provide a personalized comprehensive profile of the immune system. Aditxt's immune reprogramming technology is currently at the
pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted
organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press
release constitute "forward-looking statements" within the meaning of federal securities laws. Forward looking statements
include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning,
among other things, the Company's ongoing and planned product and business development; the Company's intellectual property
position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's
results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the
Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent
Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's
other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes
no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Media and Investor Relations Contact:
Chief Communications Officer